Aera Therapeutics
Boston
About Aera Therapeutics
Aera Therapeutics is a biotechnology company that uses its proprietary protein nanoparticle (PNP) delivery platform to help genetic medicines reach their full potential. Aera's platform, which is based on endogenous human proteins, is being developed to address the limitations of current delivery technologies and to extend the reach of genetic medicines to different tissues and applications, thereby benefiting more patients across a broader range of disease areas. In addition, Aera's licensed technology includes a therapeutic enzyme platform based on the discovery of novel, compact, and programmable gene-editing enzymes.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 101 – 250
- Total funding: $193.0M
- Funding stage: Early Stage Venture
- Last round: Series A (Feb 2023)
- Website: aeratx.com
- Phone: 1-857-600-1547
Industries & Categories
Biopharma, Biotechnology, Product Research
Social Profiles
Canonical: https://fsome.com/organization/aera-therapeutics-30521 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.